期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乳腺癌患者辅助内分泌治疗依从性研究进展 被引量：5

原文传递
导出
摘要 激素受体阳性乳腺癌患者辅助内分泌治疗的价值，已被多项大型临床研究所证实。其可以减少复发转移风险，降低患者的病死率。为达到治疗目的，患者需长期服药，疗程一般在5～10年，因此患者的依从性非常重要。与化疗相比，
作者 杨颖 胡崇珠
机构地区 保定市第一中心医院乳腺外科
出处 《中华乳腺病杂志（电子版）》 CAS 2014年第6期48-53,共6页 Chinese Journal of Breast Disease(Electronic Edition)
关键词 辅助内分泌治疗 乳腺癌患者 治疗依从性 激素受体 复发转移 长期服药 研究所 病死率
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献47

  • 1Hadji P, Ziller V, Kyvernitakis J,et al. Persistence in patientswith breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis [ J ]. Breast Cancer Res Treat, 2013,138(1) :185-191.
  • 2Nekhlyudov L, Li L, Ross-Degnan D, et al. Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer[ J]. Breast Cancer Res Treat, 2011,130(2) :681-689.
  • 3Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer[ J]. Breast Cancer Res Treat ,2011,126 (2) :529-537.
  • 4Makubate B, Donnan PT, Dewar JA, et al. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality [ J ]. Br J Cancer,2013,108 (7) : 1515- 1524.
  • 5McCowan C, Shearer J, Donnan PT, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer [ J ]. Br J Cancer, 2008,99 ( 11 ) : 1763-1768.
  • 6Lin JH, Zhang SM, Manson JE, et al. Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention [J]. Cancer Prey Res (Phila) ,2011,4(9) : 1360-1365.
  • 7Hadji P. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy [ J ]. Crit Rev Oncol Hematol,2010, 73 (2) :156-166.
  • 8Oberguggenberger AS, Sztankay M, Beer B, et al. Adherence evaluation of endocrine treatment in breast cancer: methodological aspects[ J]. BMC Cancer,2012, 12:474.
  • 9Font R, Espinas JA, Gil-Gil M, et al. Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain[ J]. Br J Cancer, 2012,107 (8) : 1249-1256.
  • 10Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer : results of the ATAC ( Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses [ J ]. Cancer,2003,98(9) :1802-1810.

二级参考文献75

  • 1周达生,姚华庭.医学系统工程与遵医行为研究[J].中国医院管理,1995,15(2):37-39. 被引量：583
  • 2卢美秀 林秋芬 魏玲玲等.个案管理与临床路径.护理杂志,1997,44(5):23-28.
  • 3Parkin D M, Bray F, Ferlay J, et al. Global Cancer Statistics, 2002[J].CA Cancer J C1in,2005,55(2):74-108.
  • 4Morsky D E, Green L W, Levine D M. ConcmTent and Predictive Validity of a Self-reported Measure of Medica- tion Adherence[ J ]. Med Care,1986,24(1):67-74.
  • 5Matthews P. Case Management Information Systems: How to Put the Pieces Together Now and Beyond Year 2000[J ]. Lippincotts Case Manag,2002,7(6):255-260.
  • 6Osborne CK, Pippen 1, Jones SE, et al.Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial[J]. J Clin Oncol,2002,20(l6): 3386-3395.
  • 7Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer[l]. J Clin Oncol,1999,17(5) :1474-1481.
  • 8Khoshnoud MR, lJifdahi B, F ohlin H, et al.Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen [J]. Breast Cancer Res Treat,2011 ,126(2) :421-430.
  • 9Hammond ME, Hayes DF, Dowsett M, et al., American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer [J]. J Clin Oncol, 2010,28(21) :2784-2795.
  • 10Fitzgibbons PL, Murphy DA, Hammond ME, et al. Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays [J]. Arch Pathol Lab Med ,2010, 134 ( 6) :930-935.

共引文献30

同被引文献96

  • 1易晓雷,易文君,冉承茂,唐中华.乳腺癌c-erbB-2的表达及其与肿瘤血管生成的关系[J].中国普通外科杂志,2005,14(4):297-299. 被引量：6
  • 2侯意枫,袁胜涛,李鹤成,吴炅,陆劲松,陆丽娟,刘刚,沈镇宙,丁健,邵志敏.雌激素受体β亚型对人乳腺癌细胞株生物学特性的影响[J].中华肿瘤杂志,2005,27(7):389-392. 被引量：10
  • 3Hadji P, Ziller V, Kyvernitakis J,et al. Persistence in patientswith breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis [ J ]. Breast Cancer Res Treat, 2013,138(1) :185-191.
  • 4Nekhlyudov L, Li L, Ross-Degnan D, et al. Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer[ J]. Breast Cancer Res Treat, 2011,130(2) :681-689.
  • 5Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer[ J]. Breast Cancer Res Treat ,2011,126 (2) :529-537.
  • 6Makubate B, Donnan PT, Dewar JA, et al. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality [ J ]. Br J Cancer,2013,108 (7) : 1515- 1524.
  • 7McCowan C, Shearer J, Donnan PT, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer [ J ]. Br J Cancer, 2008,99 ( 11 ) : 1763-1768.
  • 8Lin JH, Zhang SM, Manson JE, et al. Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention [J]. Cancer Prey Res (Phila) ,2011,4(9) : 1360-1365.
  • 9Hadji P. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy [ J ]. Crit Rev Oncol Hematol,2010, 73 (2) :156-166.
  • 10Oberguggenberger AS, Sztankay M, Beer B, et al. Adherence evaluation of endocrine treatment in breast cancer: methodological aspects[ J]. BMC Cancer,2012, 12:474.

引证文献5

二级引证文献57

中华乳腺病杂志（电子版）
2014年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部